This site is still under development. Information, features, and some organizational
aspects of the data still need further work and will change as we continue building.

Efaproxiral

Hover over a term you want explained. If you need more details, then click on the term and a new tab will open with a full details page.

What Efaproxiral Means in Everyday Medical Language

Efaproxiral, also known as RSR13, is a drug that has been studied for its potential to help treat certain cancers, especially brain tumors. It is designed to increase the amount of oxygen in tumor tissues. Tumors often have areas with low oxygen, which can make them harder to treat with radiation therapy or some chemotherapy drugs. By increasing oxygen levels, efaproxiral aims to make cancer cells more sensitive to treatment.

Why Efaproxiral Can Matter in Cancer Care

Oxygen levels in tumors affect how well treatments like radiation therapy work. Radiation is more effective when tumor cells have enough oxygen. Efaproxiral is called a radiosensitizing agent because it may help radiation therapy work better by increasing oxygen delivery to the tumor. This could potentially improve treatment outcomes for some patients. However, it is important to know that clinical trials have not shown clear benefits from efaproxiral, and it is not a standard treatment option.

What Patients Might See or Hear About Efaproxiral

Efaproxiral may appear in medical reports, treatment plans, or clinical trial information, sometimes under the name RSR13. You might hear about it if your care team is discussing experimental treatments or research studies. It can be confusing because efaproxiral is not widely used or approved as a routine cancer treatment. If you see this term, it is a good idea to ask your care team what it means for your specific situation.

Common Confusions and Clarifications

Efaproxiral is sometimes confused with substances that enhance athletic performance because it affects oxygen delivery in the body. However, there is no evidence that efaproxiral improves exercise performance in humans. It is also important to know that efaproxiral does not reach high enough levels in the blood when absorbed through the skin, lungs, or digestive system to change how oxygen binds to hemoglobin, the protein in red blood cells that carries oxygen. This means it cannot be used to boost oxygen in the body in general.

How to Use This Information and Next Steps

If you come across the term efaproxiral or RSR13 in your medical records or discussions, the best step is to ask your care team what it means for your care. This glossary entry is for education and does not replace medical advice. Your doctors can explain whether efaproxiral is relevant to your treatment, if it is part of a clinical trial, or if other options are better suited for you. Understanding the role of efaproxiral can help you make informed decisions and ask the right questions about your cancer care.

Sources

Public source information used for this glossary entry includes: